Universe Pharmaceuticals INC UPC
Biotechnology: Pharmaceutical Preparations · IPO 2021 · data as of November 13, 2026
Universe Pharmaceuticals INC (UPC) is a healthcare company listed in the US with a market value of about $8M. In fiscal year 2025 it had revenue of $17.9B and net income of -$3.7B, a net margin of -20.6%.
Its overall Stock Analiz score is 1.2 out of 5 (weak). The strongest part is future growth (2/5); the weakest is shareholder returns (0/5).
Key numbers: 5-year revenue growth of 257% a year, a 5-year average ROIC of -1%. A discounted cash flow model with moderate assumptions puts its intrinsic value about 36537% above the current price.
About Universe Pharmaceuticals INC
Universe Pharmaceuticals INC is listed in the US and classified in biotechnology: pharmaceutical preparations, IPO year 2021. Revenue went from $33M in 2019 to $17.9B in 2025, growth of about 185.1% a year. It was profitable in 3 of the last 7 years in our data. It spends 4% of revenue on research and development.
Score: 1.2 / 5
Checks passed
- Price below intrinsic value (DCF, moderate assumptions)
- 3-year revenue growth above 10% a year
- Profit margin improving
- 5-year revenue growth above 8% a year
- More cash than debt, or low debt to equity
- Liabilities below 60% of assets
Checks not passed
- P/E below 25
- P/E below the industry median
- P/FCF below 20
- PEG below 1.5
- Revenue growth above 10% last year
- 3-year free cash flow growth above 10% a year
- Strong R&D investment or growth above 20%
- 5-year EPS growth above 10% a year
Valuation
Growth and quality
Financials, last 7 years
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|---|---|---|
| Revenue | $17.9B | $23.0B | $32.3B | $40M | $48M | $31M | $33M |
| Net income | -$3.7B | -$8.7B | -$6.6B | -$8M | $11M | $8M | $8M |
| Free cash flow | -$5.3B | -$9.7B | $1.1B | -$1M | -$3M | $6M | $13M |
| EPS (diluted) | $-730.85 | $-1737.00 | $-1310.00 | $-1.57 | $2.25 | $1.50 | $1.50 |
| Net margin | -20.6% | -37.9% | -20.4% | -19.7% | 23.6% | 24.6% | 22.7% |
| ROIC | -4.0% | -12.3% | -11.2% | -0.0% | 21.9% | 32.7% | 61.6% |
From the company’s 10-K and 10-Q filings with the SEC. TTM = trailing twelve months.
Frequently asked questions
Is Universe Pharmaceuticals INC stock undervalued?
Our DCF model with moderate assumptions puts its intrinsic value about 36537% above the current market value. A model is a range, not a promise; try your own assumptions in the DCF calculator.
Does Universe Pharmaceuticals INC pay a dividend?
Not currently.
Is Universe Pharmaceuticals INC a good stock to buy?
We do not give buy or sell advice. Universe Pharmaceuticals INC scores 1.2 out of 5 on our five checks (value, growth, track record, financial health and shareholder returns); the checks above show why.
Similar companies
Generated from SEC filings, analyst consensus estimates and market prices, rebuilt every day. Educational information, not investment advice.